# Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

> **NCT03150004** · PHASE2 · TERMINATED · sponsor: **Medical College of Wisconsin** · enrollment: 53 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
- **DRUG:** Cladribine and Cytarabine (CLLDAC) Regimen

## Key facts

- **NCT ID:** NCT03150004
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-14
- **Primary completion:** 2025-03-14
- **Final completion:** 2025-03-14
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** No longer have funding support to complete the pharmacogenetics component.
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150004, "Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03150004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*